1. Home
  2. EIM vs LYEL Comparison

EIM vs LYEL Comparison

Compare EIM & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eaton Vance Municipal Bond

EIM

Eaton Vance Municipal Bond

HOLD

Current Price

$9.92

Market Cap

499.9M

Sector

Finance

ML Signal

HOLD

Logo Lyell Immunopharma Inc.

LYEL

Lyell Immunopharma Inc.

HOLD

Current Price

$24.23

Market Cap

556.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EIM
LYEL
Founded
N/A
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
499.9M
556.1M
IPO Year
2002
2021

Fundamental Metrics

Financial Performance
Metric
EIM
LYEL
Price
$9.92
$24.23
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$30.60
AVG Volume (30 Days)
146.8K
76.4K
Earning Date
01-01-0001
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$36,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$8,712.13
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.41
$0.39
52 Week High
$10.54
$45.00

Technical Indicators

Market Signals
Indicator
EIM
LYEL
Relative Strength Index (RSI) 58.15 59.93
Support Level $9.86 $21.27
Resistance Level $10.02 $27.30
Average True Range (ATR) 0.10 1.65
MACD 0.03 0.41
Stochastic Oscillator 95.56 90.43

Price Performance

Historical Comparison
EIM
LYEL

About EIM Eaton Vance Municipal Bond

Eaton Vance Municipal Bond Fund is a non-diversified closed-end management investment company. It consists of Municipal bond fund, California municipal bond fund, and New York municipal bond fund. The company's investment objective is to provide current income exempt from regular federal income tax, alternative minimum tax, and taxes in specified states. Its investment plan is to invest in higher quality bonds.

About LYEL Lyell Immunopharma Inc.

Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.

Share on Social Networks: